172 related articles for article (PubMed ID: 14996706)
1. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Forero A; Weiden PL; Vose JM; Knox SJ; LoBuglio AF; Hankins J; Goris ML; Picozzi VJ; Axworthy DB; Breitz HB; Sims RB; Ghalie RG; Shen S; Meredith RF
Blood; 2004 Jul; 104(1):227-36. PubMed ID: 14996706
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
3. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
Weiden PL; Breitz HB
Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
[TBL] [Abstract][Full Text] [Related]
4. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Forero-Torres A; Shen S; Breitz H; Sims RB; Axworthy DB; Khazaeli MB; Chen KH; Percent I; Besh S; LoBuglio AF; Meredith RF
Cancer Biother Radiopharm; 2005 Aug; 20(4):379-90. PubMed ID: 16114986
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
Pagel JM; Lin Y; Hedin N; Pantelias A; Axworthy D; Stone D; Hamlin DK; Wilbur DS; Press OW
Blood; 2006 Jul; 108(1):328-36. PubMed ID: 16556891
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
[TBL] [Abstract][Full Text] [Related]
7. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
9. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
11. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
12. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Park SI; Shenoi J; Frayo SM; Hamlin DK; Lin Y; Wilbur DS; Stayton PS; Orgun N; Hylarides M; Buchegger F; Kenoyer AL; Axtman A; Gopal AK; Green DJ; Pagel JM; Press OW
Clin Cancer Res; 2011 Dec; 17(23):7373-82. PubMed ID: 21976541
[TBL] [Abstract][Full Text] [Related]
13. Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.
Green DJ; Frayo SL; Lin Y; Hamlin DK; Fisher DR; Frost SH; Kenoyer AL; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; O'Steen S; Orcutt KD; Wilbur DS; Wittrup KD; Press OW
Cancer Res; 2016 Nov; 76(22):6669-6679. PubMed ID: 27590740
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
Kaminski MS; Zasadny KR; Francis IR; Fenner MC; Ross CW; Milik AW; Estes J; Tuck M; Regan D; Fisher S; Glenn SD; Wahl RL
J Clin Oncol; 1996 Jul; 14(7):1974-81. PubMed ID: 8683227
[TBL] [Abstract][Full Text] [Related]
15. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.
Press OW; Corcoran M; Subbiah K; Hamlin DK; Wilbur DS; Johnson T; Theodore L; Yau E; Mallett R; Meyer DL; Axworthy D
Blood; 2001 Oct; 98(8):2535-43. PubMed ID: 11588052
[TBL] [Abstract][Full Text] [Related]
16. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Green DJ; O'Steen S; Lin Y; Comstock ML; Kenoyer AL; Hamlin DK; Wilbur DS; Fisher DR; Nartea M; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; Orcutt KD; Wittrup KD; Press OW
Blood; 2018 Feb; 131(6):611-620. PubMed ID: 29158362
[TBL] [Abstract][Full Text] [Related]
17. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Park SI; Shenoi J; Pagel JM; Hamlin DK; Wilbur DS; Orgun N; Kenoyer AL; Frayo S; Axtman A; Bäck T; Lin Y; Fisher DR; Gopal AK; Green DJ; Press OW
Blood; 2010 Nov; 116(20):4231-9. PubMed ID: 20702781
[TBL] [Abstract][Full Text] [Related]
18. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.
Pantelias A; Pagel JM; Hedin N; Saganic L; Wilbur S; Hamlin DK; Wilbur DS; Lin Y; Stone D; Axworthy D; Gopal AK; Press OW
Blood; 2007 Jun; 109(11):4980-7. PubMed ID: 17303693
[TBL] [Abstract][Full Text] [Related]
19. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
20. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]